Adaptimmune Total Stockholder Equity vs Total Liab Analysis

ADAP Stock

USD 1.13 0.12 11.88%

Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Total Stockholder Equity and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Total Stockholder Equity vs Total Liab

Total Stockholder Equity vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Total Stockholder Equity account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Adaptimmune Therapeutics' Total Stockholder Equity and Total Liab is -0.01. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Total Liab in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Total Stockholder Equity and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Adaptimmune Therapeutics Plc are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Stockholder Equity i.e., Adaptimmune Therapeutics' Total Stockholder Equity and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

As of 06/01/2024, Selling General Administrative is likely to drop to about 37.2 M. In addition to that, Tax Provision is likely to drop to about 832.7 K

	2021	2022	2023	2024 (projected)
Net Interest Income	1.1M	1.5M	6.0M	6.3M
Interest Income	1.1M	1.5M	6.0M	6.3M

Net Interest Income Interest Income

Adaptimmune Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Short Term Debt	Property Plant Equipment	Net Tangible Assets
Total Assets		0.31	0.61	0.77	0.63	-0.38	-0.6	0.6	0.63	0.66	0.39	0.96	0.15	0.83	0.59	0.7	0.79	0.63	0.47	0.99	0.77	0.2	-0.79	0.04	0.51	0.83
Other Current Liab	0.31		0.74	-0.04	0.5	0.19	-0.51	0.21	-0.08	0.51	-0.04	0.18	0.18	0.4	0.42	0.49	0.52	0.52	0.4	0.24	0.39	0.06	0.01	-0.08	0.41	0.0
Total Current Liabilities	0.61	0.74		0.17	0.7	-0.17	-0.65	0.66	0.38	0.73	0.2	0.47	0.36	0.68	0.61	0.58	0.7	0.74	0.61	0.54	0.66	0.2	-0.42	0.05	0.67	0.24
Total Stockholder Equity	0.77	-0.04	0.17		0.12	-0.25	-0.01	0.34	0.53	0.26	0.62	0.85	-0.31	0.38	-0.05	0.35	0.34	-0.01	-0.07	0.81	0.29	0.49	-0.78	0.22	-0.02	0.99
Property Plant And Equipment Net	0.63	0.5	0.7	0.12		-0.02	-0.96	0.67	0.18	0.93	0.18	0.42	0.58	0.94	0.81	0.79	0.89	0.86	0.92	0.52	0.94	-0.22	-0.47	-0.38	0.94	0.23
Net Debt	-0.38	0.19	-0.17	-0.25	-0.02		0.11	-0.11	-0.87	0.08	0.07	-0.46	-0.29	-0.22	-0.31	0.13	-0.06	-0.3	-0.13	-0.45	-0.26	-0.24	0.46	-0.71	-0.09	-0.27
Retained Earnings	-0.6	-0.51	-0.65	-0.01	-0.96	0.11		-0.54	-0.19	-0.84	0.04	-0.41	-0.67	-0.91	-0.92	-0.71	-0.89	-0.93	-0.93	-0.5	-0.93	0.36	0.33	0.38	-0.91	-0.14
Accounts Payable	0.6	0.21	0.66	0.34	0.67	-0.11	-0.54		0.31	0.75	0.46	0.46	0.21	0.67	0.44	0.63	0.66	0.52	0.55	0.52	0.63	0.11	-0.58	-0.05	0.57	0.41
Cash	0.63	-0.08	0.38	0.53	0.18	-0.87	-0.19	0.31		0.16	0.27	0.68	0.26	0.42	0.3	0.07	0.24	0.34	0.22	0.68	0.43	0.52	-0.75	0.65	0.25	0.56
Non Current Assets Total	0.66	0.51	0.73	0.26	0.93	0.08	-0.84	0.75	0.16		0.34	0.44	0.32	0.86	0.66	0.85	0.94	0.71	0.75	0.54	0.83	-0.14	-0.51	-0.38	0.81	0.34
Other Assets	0.39	-0.04	0.2	0.62	0.18	0.07	0.04	0.46	0.27	0.34		0.37	-0.21	0.28	-0.24	0.27	0.18	-0.15	0.05	0.37	0.2	0.54	-0.68	0.1	0.14	0.6
Cash And Short Term Investments	0.96	0.18	0.47	0.85	0.42	-0.46	-0.41	0.46	0.68	0.44	0.37		0.05	0.68	0.44	0.54	0.6	0.47	0.29	0.99	0.62	0.31	-0.78	0.18	0.31	0.89
Net Receivables	0.15	0.18	0.36	-0.31	0.58	-0.29	-0.67	0.21	0.26	0.32	-0.21	0.05		0.56	0.62	-0.01	0.35	0.64	0.85	0.11	0.67	-0.18	-0.12	-0.04	0.76	-0.16
Common Stock Total Equity	0.83	0.4	0.68	0.38	0.94	-0.22	-0.91	0.67	0.42	0.86	0.28	0.68	0.56		0.8	0.75	0.91	0.84	0.87	0.75	0.99	-0.07	-0.66	-0.22	0.88	0.5
Non Current Liabilities Total	0.59	0.42	0.61	-0.05	0.81	-0.31	-0.92	0.44	0.3	0.66	-0.24	0.44	0.62	0.8		0.64	0.79	0.98	0.8	0.52	0.82	-0.39	-0.23	-0.27	0.78	0.05
Other Current Assets	0.7	0.49	0.58	0.35	0.79	0.13	-0.71	0.63	0.07	0.85	0.27	0.54	-0.01	0.75	0.64		0.85	0.66	0.5	0.61	0.66	-0.17	-0.45	-0.44	0.57	0.38
Other Stockholder Equity	0.79	0.52	0.7	0.34	0.89	-0.06	-0.89	0.66	0.24	0.94	0.18	0.6	0.35	0.91	0.79	0.85		0.81	0.74	0.69	0.87	-0.21	-0.48	-0.35	0.76	0.43
Total Liab	0.63	0.52	0.74	-0.01	0.86	-0.3	-0.93	0.52	0.34	0.71	-0.15	0.47	0.64	0.84	0.98	0.66	0.81		0.84	0.56	0.86	-0.27	-0.3	-0.21	0.83	0.09
Property Plant And Equipment Gross	0.47	0.4	0.61	-0.07	0.92	-0.13	-0.93	0.55	0.22	0.75	0.05	0.29	0.85	0.87	0.8	0.5	0.74	0.84		0.38	0.92	-0.23	-0.36	-0.28	0.96	0.08
Total Current Assets	0.99	0.24	0.54	0.81	0.52	-0.45	-0.5	0.52	0.68	0.54	0.37	0.99	0.11	0.75	0.52	0.61	0.69	0.56	0.38		0.69	0.26	-0.78	0.12	0.4	0.86
Common Stock	0.77	0.39	0.66	0.29	0.94	-0.26	-0.93	0.63	0.43	0.83	0.2	0.62	0.67	0.99	0.82	0.66	0.87	0.86	0.92	0.69		-0.1	-0.61	-0.2	0.91	0.42
Short Long Term Debt Total	0.2	0.06	0.2	0.49	-0.22	-0.24	0.36	0.11	0.52	-0.14	0.54	0.31	-0.18	-0.07	-0.39	-0.17	-0.21	-0.27	-0.23	0.26	-0.1		-0.51	0.71	-0.12	0.46
Common Stock Shares Outstanding	-0.79	0.01	-0.42	-0.78	-0.47	0.46	0.33	-0.58	-0.75	-0.51	-0.68	-0.78	-0.12	-0.66	-0.23	-0.45	-0.48	-0.3	-0.36	-0.78	-0.61	-0.51		-0.28	-0.43	-0.81
Short Term Debt	0.04	-0.08	0.05	0.22	-0.38	-0.71	0.38	-0.05	0.65	-0.38	0.1	0.18	-0.04	-0.22	-0.27	-0.44	-0.35	-0.21	-0.28	0.12	-0.2	0.71	-0.28		-0.27	0.19
Property Plant Equipment	0.51	0.41	0.67	-0.02	0.94	-0.09	-0.91	0.57	0.25	0.81	0.14	0.31	0.76	0.88	0.78	0.57	0.76	0.83	0.96	0.4	0.91	-0.12	-0.43	-0.27		0.11
Net Tangible Assets	0.83	0.0	0.24	0.99	0.23	-0.27	-0.14	0.41	0.56	0.34	0.6	0.89	-0.16	0.5	0.05	0.38	0.43	0.09	0.08	0.86	0.42	0.46	-0.81	0.19	0.11

Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Other Current Liab	23.4M	27.1M	29.9M	33.5M	30.3M	21.7M
Total Current Liabilities	34.3M	39.1M	62.5M	64.5M	72.8M	44.6M
Total Stockholder Equity	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Property Plant And Equipment Net	51.9M	46.7M	51.4M	71.5M	71.7M	75.3M
Net Debt	(25.0M)	(33.2M)	(124.5M)	(85.0M)	(118.8M)	(112.8M)
Retained Earnings	(455.7M)	(585.8M)	(743.8M)	(909.3M)	(1.0B)	(972.0M)
Accounts Payable	6.4M	6.4M	8.1M	4.8M	8.1M	5.5M
Cash	50.4M	56.9M	149.9M	108.0M	144.0M	112.8M
Non Current Assets Total	61.1M	53.0M	54.1M	73.5M	75.1M	39.1M
Other Assets	7.0M	4.6M	1.7M	1.6M	1.8M	1.7M
Cash And Short Term Investments	89.5M	368.2M	369.6M	204.6M	146.9M	202.8M
Net Receivables	(1.5M)	139K	752K	7.4M	46.9M	49.3M
Common Stock Total Equity	939K	943K	1.3M	1.3M	1.5M	1.6M
Liabilities And Stockholders Equity	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Non Current Liabilities Total	23.6M	70.8M	201.0M	182.5M	170.3M	178.8M
Other Current Assets	30.9M	29.8M	45.1M	43.3M	13.7M	19.3M
Other Stockholder Equity	585.6M	935.7M	959.6M	990.7M	1.1B	535.2M
Total Liab	57.9M	109.9M	263.6M	247.0M	243.1M	255.3M
Property Plant And Equipment Gross	51.9M	46.7M	51.4M	71.5M	130.9M	137.5M
Total Current Assets	120.5M	398.2M	415.5M	255.4M	207.6M	229.0M
Accumulated Other Comprehensive Income	(7.3M)	(10.0M)	(11.1M)	(875K)	(3.7M)	(3.6M)
Common Stock	943K	1.3M	1.3M	1.4M	1.9M	2.0M
Short Long Term Debt Total	25.5M	23.7M	25.5M	23.1M	25.2M	38.5M
Common Stock Shares Outstanding	105.0M	142.5M	155.8M	161.2M	201.1M	129.5M
Property Plant Equipment	31.1M	27.8M	30.5M	71.5M	82.3M	86.4M
Net Tangible Assets	121.4M	339.5M	205.0M	81.4M	93.7M	89.0M
Non Currrent Assets Other	7.0M	4.6M	1.7M	1.6M	3.0M	3.6M
Short Term Investments	39.1M	311.3M	219.6M	96.6M	2.9M	2.8M
Other Liab	598K	49.9M	177.9M	162.2M	186.5M	195.8M
Inventory	1.5M	2.1M	746K	1.3M	1.3M	1.4M
Intangible Assets	2.2M	1.7M	1M	442K	330K	313.5K
Capital Surpluse	574.2M	585.6M	935.7M	959.6M	1.1B	657.5M
Retained Earnings Total Equity	(318.5M)	(455.7M)	(585.8M)	(743.8M)	(669.5M)	(636.0M)
Non Current Liabilities Other	23.6M	70.8M	201.0M	1.3M	1.4M	1.3M
Net Invested Capital	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Net Working Capital	86.1M	359.1M	352.9M	190.9M	134.8M	233.6M
Capital Stock	943K	1.3M	1.3M	1.4M	1.9M	1.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adaptimmune Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptimmune Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Adaptimmune Therapeutics Plc Stock:

How To Invest In Adaptimmune

Details

Is Adaptimmune Stock a good investment?

Details

What is Adaptimmune Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Adaptimmune Stock analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.73)

Revenue Per Share

0.3

Quarterly Revenue Growth

(0.98)

Return On Assets

(0.28)

Return On Equity

(1.88)

The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptimmune Total Stockholder Equity vs Total Liab Analysis

Total Stockholder Equity vs Total Liab

Total Stockholder Equity vs Total Liab Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Total Liab

Adaptimmune Therapeutics fundamental ratios Correlations

Adaptimmune Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptimmune Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Adaptimmune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Total Equity
Total Liab	+ 0.98	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets

Retained Earnings	- 0.96	Property Plant And Equipment Net
Common Stock	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings